Literature DB >> 12435686

Antimicrobial susceptibilities of diverse Bacillus anthracis isolates.

Pamala R Coker1, Kimothy L Smith, Martin E Hugh-Jones.   

Abstract

A test of 25 genetically diverse isolates of Bacillus anthracis was conducted to determine their susceptibility to seven clinically relevant antimicrobial agents. Etest strips (AB BIODISK, Solna, Sweden) were used to measure the MICs for the isolates. Using the National Committee for Clinical Laboratory Standards MIC breakpoints for staphylococci, three isolates were found to be resistant to penicillin and five were found to be resistant to cefuroxime. The penicillin-resistant isolates were negative for beta-lactamase production. Continued surveillance of B. anthracis field isolates is recommended to monitor antimicrobial susceptibility.

Entities:  

Mesh：

Year:  2002        PMID： 12435686      PMCID： PMC132748          DOI： 10.1128/AAC.46.12.3843-3845.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  THE CHEMISTRY OF THE CELL WALLS OF BACILLUS ANTHRACIS: THE EFFECT OF PENICILLIN.

Authors:  R S RATNEY
Journal:  Biochim Biophys Acta       Date:  1965-03-01

2.  Antimicrobial susceptibility of Bacillus anthracis.

Authors:  M Doğanay; N Aydin
Journal:  Scand J Infect Dis       Date:  1991

3.  Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.

Authors:  M Jasmine Mohammed; Chung K Marston; Tanja Popovic; Robbin S Weyant; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-10-26       Impact factor: 17.586

5.  Treatment of anthrax.

Authors:  H Gold
Journal:  Fed Proc       Date:  1967-09

6.  Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis.

Authors:  P Keim; L B Price; A M Klevytska; K L Smith; J M Schupp; R Okinaka; P J Jackson; M E Hugh-Jones
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

7.  PURIFICATION AND PROPERTIES OF PENICILLINASES FROM TWO STRAINS OF BACILLUS LICHENIFORMIS: A CHEMICAL, PHYSICOCHEMICAL AND PHYSIOLOGICAL COMPARISON.

Authors:  M R POLLOCK
Journal:  Biochem J       Date:  1965-03       Impact factor: 3.857
  7 in total
  15 in total

1.  Beta-lactamase gene expression in a penicillin-resistant Bacillus anthracis strain.

Authors:  Yahua Chen; Fred C Tenover; Theresa M Koehler
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design.

Authors:  Brad C Bennett; Qun Wan; Md Faiz Ahmad; Paul Langan; Chris G Dealwis
Journal:  J Struct Biol       Date:  2009-05       Impact factor: 2.867

3.  In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species.

Authors:  Diane M Citron; Maria D Appleman
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim.

Authors:  Esther W Barrow; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads.

Authors:  Tammy M Joska; Amy C Anderson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

6.  In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.

Authors:  Esther W Barrow; Jürg Dreier; Stefan Reinelt; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

7.  Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.

Authors:  Suresh K Tipparaju; Debbie C Mulhearn; Gary M Klein; Yufeng Chen; Subhasish Tapadar; Molly H Bishop; Shuo Yang; Juan Chen; Mahmood Ghassemi; Bernard D Santarsiero; James L Cook; Mary Johlfs; Andrew D Mesecar; Michael E Johnson; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2008-08       Impact factor: 3.466

8.  MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.

Authors:  Peter C B Turnbull; Nicky M Sirianni; Carlos I LeBron; Marian N Samaan; Felicia N Sutton; Anatalio E Reyes; Leonard F Peruski
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  Daptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrity.

Authors:  Yu-hua Xing; Wei Wang; Su-qin Dai; Ti-yan Liu; Jun-jie Tan; Guo-long Qu; Yu-xia Li; Yan Ling; Gang Liu; Xue-qi Fu; Hui-peng Chen
Journal:  Acta Pharmacol Sin       Date:  2013-12-23       Impact factor: 6.150

10.  In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin.

Authors:  Lance B Price; Amy Vogler; Talima Pearson; Joseph D Busch; James M Schupp; Paul Keim
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.